BAMF
BEAM icon

BI Asset Management Fondsmaeglerselskab’s Beam Therapeutics BEAM Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,714
Closed -$33K – 764
2025
Q1 		$33K Buy
+1,714
New +$44.9K ﹤0.01% 877

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's BEAM Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 1,714 shares — an estimated $33K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in BEAM in Q1 2025 and held it in 1 quarter. The position peaked at $33K in Q1 2025. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 1,714 Beam Therapeutics shares in Q2 2025, an estimated $33K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Beam Therapeutics in Q1 2025 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Beam Therapeutics position peaked at $33K in Q1 2025.
  • 217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.